96 results
Page 2 of 5
8-K
EX-10.1
b4tyz925655g
24 Mar 22
Entry into a Material Definitive Agreement
4:30pm
424B5
p5mqya
24 Mar 22
Prospectus supplement for primary offering
4:15pm
424B5
61xp b7y8iegced
20 Aug 21
Prospectus supplement for primary offering
4:46pm
8-K
EX-1.1
eo7x o4lxwhia
20 Aug 21
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
tgo9k19 0m1
17 Jun 21
PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR the Development of RX-3117
11:35am
8-K
EX-99.1
dqzrxl0
13 May 21
Processa Pharmaceuticals Announces First Quarter 2021 Results and Provides Corporate Update
5:28pm